Breaks Categories: News

FridayApr 01, 2022 1:27 pm

PsychedelicNewsBreaks – LFTD Partners Inc. (LIFD) Announces Record Revenue for Q4 and Full Year 2021

LFTD Partners (OTCQB: LIFD), the corporate parent of leading cannabis and psychedelics-lifestyle and consumer packaged goods company Lifted Made, reported record revenue for fourth quarter and full year 2021, and its sixth consecutive quarter of positive GAAP-basis earnings per share. Among the financial highlights for the 2021 fiscal year, LFTD Partners reported a 492% increase in revenue to $31,656,932, up from $5,344,320 in 2020. “Our tremendous growth and profitability during 2021 was a reflection of the team and infrastructure that we have built over the years and is a testament to the power of a true consumer-run business,” said Nicholas…

Continue Reading

ThursdayMar 31, 2022 2:23 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Announces Filing of Year-End 2021 Results

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the filing of its Annual Report on Form 20-F for the year ended Dec. 31, 2021, audited financial results for the fourth quarter and full year then ended and accompanying management discussion and analysis. According to the announcement, the filings are available for review under the company's SEDAR profile at www.sedar.com and its EDGAR profile at www.sec.gov. To view the full press release, visit https://ibn.fm/LPlQS About FSD Pharma Inc. FSD Pharma is a biotechnology company…

Continue Reading

ThursdayMar 31, 2022 1:03 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Commencement of Kernel Flow(R) Feasibility Study, Marking Exciting Moment for Psychedelic Drug Development

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that the first visit has been conducted in a Cybin-sponsored feasibility study. The study will focus on evaluating Kernel’s quantitative neuroimaging technology, Flow, to measure ketamine’s psychedelic effects on cerebral cortex hemodynamics. “The commencement of the Kernel feasibility study marks a truly exciting moment, not only for Cybin and Kernel, but also for the entire field of psychedelic drug development. To this point, studies have had to rely on subjective patient reporting,” said Cybin CEO Doug Drysdale. “By deploying the innovative Flow technology,…

Continue Reading

ThursdayMar 31, 2022 11:19 am

PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Enters Agreement to Significantly Advance Technologies ‘Closer to the Clinic’

Silo Pharma (OTCQB: SILO) is a developmental stage biopharmaceutical company focused on the use of psychedelics as a therapeutic. Silo Pharma today announced its entry into an agreement with Frontage Laboratories, a contract research organization (“CRO”) providing integrated, science-driven, product development services throughout the drug discovery and development process that enable life science companies to achieve their drug development goals. “This agreement significantly advances our Central Nervous System Peptide, SPU-16, and our Joint Homing Peptide, SPU-21 technologies closer to the clinic,” said Eric Weisblum, CEO of Silo Pharma. “These solutions have the potential to enhance the therapeutic effect of current…

Continue Reading

ThursdayMar 31, 2022 11:10 am

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces New Clinic Openings as Company’s Expansion Accelerates

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, is opening Ketamine Wellness Centers (“KWC”) in Salt Lake City and Reno, Nevada, with additional locations planned to open this year. The company also announced that it is adding SPRAVATO(R), the first FDA-approved nasal spray, as a treatment option at three of its ketamine centers; the spray is intended to treat adults with treatment-resistant depression and depressive symptoms of major depressive disorder. In addition, the the company’s Delic Labs received Health Canada 56 exemptions to perform research and development work for several substances, including MDMA,…

Continue Reading

WednesdayMar 30, 2022 12:59 pm

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Subsidiary Expands Treatment Options to Add FDA-Approved Esketamine Nasal Spray

Delic Holdings’ (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) subsidiary, Ketamine Wellness Centers (“KWC”), the largest ketamine therapy provider in the U.S., has expanded its treatment options to include SPRAVATO(R) nasal spray. KWC clinics located in Houston, Las Vegas and Seattle will begin offering this treatment option on April 1. According to the announcement, SPRAVATO is taken with an oral antidepressant and is the first FDA-approved esketamine nasal spray for adults with treatment-resistant depression (“TRD”) or to treat depressive symptoms in adults with major depressive disorder (“MDD”) with suicidal thoughts or actions. Patients interested in the treatment option will first undergo…

Continue Reading

TuesdayMar 29, 2022 12:15 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Significant Milestone Toward Advancing CYB003 Program

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced the completion of in vivo preclinical studies evaluating its deuterated psilocybin analog CYB003 for the potential treatment of major depressive disorder (“MDD”). According to the update, data from the studies demonstrate that CYB003 is well-tolerated following several doses in multiple species and support the advancement toward an investigational new drug (“IND”) filing with the U.S. Food and Drug Administration (“FDA”) for a Phase 1/2a first-in-human clinical trial in patients with MDD. “The completion of these in vivo preclinical studies for CYB003 represents a…

Continue Reading

FridayMar 25, 2022 10:58 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Subsidiary Achieves Milestone Outlined in Contribution Agreement

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced that its wholly controlled subsidiary, Adelia Therapeutics Inc., has achieved a key milestone. The milestones were identified in the Dec. 4, 2020, contribution agreement between Cybin and Adelia and include Year 1 Q4 (vi), Year 2 Q2 (ii), Year 2 Q2 (v) and Year 2, Q3 (iii). Others involved in the agreement include Cybin Corp., Cybin US Holdings Inc. and the previous shareholders of Adelia. According to the agreement, Adelia shareholders will be issued 90,546.0 Class B shares in Cybin; those shares are exchangeable…

Continue Reading

ThursdayMar 24, 2022 2:12 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Commences Participant Recruitment in Feasibility Study Using Kernel Flow Technology

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that its company-sponsored feasibility study using Kernel’s quantitative neuroimaging technology, Kernel Flow, is actively recruiting participants. The study will evaluate participants’ experience wearing Kernel Flow while in an altered state of consciousness following the administration of ketamine. “The feasibility study using Kernel Flow offers an opportunity for researchers and our study participants to quantifiably gather information on a psychedelic experience,” Cybin’s Chief Executive Officer Doug Drysdale said in the press release. “Until now, our understanding of the psychedelic experience has been fairly subjective.…

Continue Reading

ThursdayMar 24, 2022 1:42 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces IRB Approval for Planned Smoking Cessation Study

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, has received conditional approval from the Institutional Review Board ("IRB") for its planned multisite phase 2b smoking cessation trial. According to the announcement, Johns Hopkins University will serve as the lead investigational site for the study. The company anticipates submitting its IND application in the second quarter, with hopes that the study will begin shortly thereafter. Calling the approval a “significant milestone,” the company noted that its mission is to provide safer, more effective solutions to address nicotine dependence…

Continue Reading